Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
Rhea-AI Summary
Standard BioTools (NASDAQ: LAB) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will disclose its Q1 2025 results on Tuesday, May 6, 2025, after the market closes.
A conference call and webcast are scheduled for the same day at 4:30 p.m. ET. Investors can participate through the following dial-in numbers:
- US domestic: (888) 346-3970
- International: (412) 902-4297
The webcast will be accessible through the company's Investor Relations page and will be archived at investors.standardbio.com for future reference.
Positive
- None.
Negative
- None.
News Market Reaction – LAB
On the day this news was published, LAB gained 6.72%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress.
Individuals can access the conference call by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary SomaScan, mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
©2025 Standard BioTools Inc. All rights reserved.
Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contact:
David Holmes
ir@standardbio.com
FAQ
When will Standard BioTools (LAB) release Q1 2025 earnings?
How can investors join Standard BioTools (LAB) Q1 2025 earnings call?
Where can I find the replay of LAB's Q1 2025 earnings webcast?
What time is Standard BioTools (LAB) Q1 2025 earnings call?
